Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 20;13:3291–3301. doi: 10.2147/OTT.S244652

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Cheng et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Exosomal lncRNA RAMP2-AS1 promotes angiogenesis via modulation of miR-2355-5p/VEGFR2 axis. (A) Cell proliferation was detected in HUVECs treated with Exo/SW1353, si-RAMP2-AS1 and miR-2355-5p inhibitors. (B, D) Tube formation assay of HUVECs treated with Exo/SW1353, si-RAMP2-AS1 and miR-2355-5p inhibitors. (C, E) Transwell migration assay of HUVECs treated with Exo/SW1353, si-RAMP2-AS1 and miR-2355-5p inhibitors. (F) The transfection efficiency of VEGFR2 overexpression plasmid was measured by Western blot. (G) Cell proliferation was detected in HUVECs treated with Exo/SW1353, si-RAMP2-AS1 and VEGFR2 overexpression plasmid. (H, J) Tube formation assay of HUVECs treated with Exo/SW1353, si-RAMP2-AS1 and VEGFR2 overexpression plasmid. (I, K) Transwell migration assay of HUVECs treated with Exo/SW1353, si-RAMP2-AS1 and VEGFR2 overexpression plasmid. *P<0.05.